Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry.

Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry. Abstract Text:

Catherine Z Matthews,Eric J Woolf,

A method for determination of a gamma-secretase inhibitor, cis-3-[4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid (A), in human plasma and cerebrospinal fluid (CSF) has been developed to support the clinical investigation of compound A for its potential treatment of Alzheimer's disease. The method is based on HPLC with atmospheric pressure chemical ionization tandem mass spectrometric detection (APCI-MS/MS) in the negative ionization mode using a heated nebulizer interface. The addition of phosphoric acid at the ratio of 10-30muL per milliliter of human plasma or CSF was required during clinical sample collection to stabilize an acylglucuronide metabolite (C), which was potentially present in human plasma and CSF. Tween 20 (10% solution) was added at the ratio of 20muL per milliliter of CSF during CSF sample collection to prevent the loss of compound A during the storage of clinical samples. The compound A and its analog internal standard (B) in treated plasma or CSF were isolated from human plasma or CSF using solid phase extraction (SPE) in the 96 well format. The isolated analyte and internal standard were chromatographed on a Phenomenex Synergi((R)) Polar RP analytical column (50mmx3.0mm, 4mum), using a mobile phase consisting of 60/40 (v/v, %) acetonitrile/water at a flow-rate of 0.5mL/min. Tandem mass spectrometric detection was performed using a Sciex API 3000 tandem mass spectrometer operated in the multiple reaction monitoring (MRM) mode using precursor to product ion transitions of 441-->175 for A and 469-->175 for B, respectively. The assays were validated over the concentration range of 0.5-200ng/mL for human plasma and CSF. Replicate analyses (n=5) of spiked standards for both assays yielded a linear response with coefficients of variation less than 7% and accuracy within 5% of the nominal concentrations. In addition, the assays were automated to improve sample throughput by utilizing a Packard Multi PROBEII automated liquid handling system and a Tom-Tec Quadra 96 system. Numerous clinical studies have been supported using these assays.

Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry. Publishing Authors By Initials

CZ Matthews,EJ Woolf,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of chromatography. B, Analytical technolog

VOLUME: 863

Page Numbers: 36-45

Journal Abbreviation: J. Chromatogr. B Analyt. Techn

ISSN: 1570-0232

DAY: 6

MONTH: 01

YEAR: 2008

Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101139554

Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry.

AFFILIATION: Merck Research Laboratories, Department of Drug Metabolism, Sumneytown Pike, WP75A-303 West Point, PA 19486, USA.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Chromatogr B Analyt Technol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry Related Publications

• ATF3 increases the intrinsic growth state of DRG neurons to enhance peripheral nerve regeneration.
• C-primary afferent fibre mediated inhibitions in the dorsal horn of the decerebrate-spinal rat.
• Citrus aurantium used for weight loss by an adolescent with anorexia nervosa.
• Coincident congenital anomalies of the reproductive and urologic tract--didelphys with 58 days between births of viable twins.
• Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity.
• Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry.
• Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS.
• Dietary Supplements: Inpatient Policies in US Children's Hospitals.
• Educational psychology as applied to vision training.
• Estimation of phenylpyruvic acid.
• External validity reporting in prevention research.
• GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence.
• Immunohistochemical analysis of Sonic hedgehog signalling in normal human urinary tract development.
• Investigations on genetic aspects of carcinoma of the stomach and breast.
• Maternal effect involved in the inheritance of abnormal growths in the head region of Drosophila melanogaster.
• Monitoring cyanide and thiocyanate concentrations during infusion of sodium nitroprusside in children.
• On fulminant tuberculous septicemia with leukopenia.
• Perinatal renal disease.
• Perspectives on human perinatal renal tract disease.
• Pituitary ACTH secretion altered in cortisol nonsuppression?
• Rapid calculation of standard deviations.
• Rhodopsin exhibits a preference for solvation by polyunsaturated docosohexaenoic acid.
• Ro5-4864 promotes neonatal motor neuron survival and nerve regeneration in adult rats.
• Tests for phenylketonuria.
• The meaning of translational research and why it matters.
• The neuropathic pain triad: neurons, immune cells and glia.
• The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity.
• UEMS charter on the training of rheumatologists in Europe.
• Understanding the Hofmeister effect in interactions between chaotropic anions and lipid bilayers: molecular dynamics simulations.
• Virginia Woolf. An outline of a study on her personality, illness and work.